-+ 0.00%
-+ 0.00%
-+ 0.00%

CARsgen presents updated EHA data from CT0596 allogeneic BCMA CAR-T study in relapsed/refractory multiple myeloma

PUBT·06/15/2026 00:01:47
Listen to the news
CARsgen presents updated EHA data from CT0596 allogeneic BCMA CAR-T study in relapsed/refractory multiple myeloma
  • CARsgen reported updated investigator-initiated study results for allogeneic CAR-T candidates CT0596 and CT1190B at the 2026 EHA Congress.
  • The CT0596 poster was presented June 12, 2026, citing favorable early tolerability with encouraging signs of activity in relapsed or refractory multiple myeloma.
  • The CT1190B poster was presented June 13, 2026, citing early tolerability with preliminary activity signals in relapsed or refractory B-cell non-Hodgkin lymphoma.
  • Phase Ib trials are planned in 2026 for CT0596 in multiple myeloma and primary plasma cell leukemia, for CT1190B in B-cell non-Hodgkin lymphoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260615-12201903), on June 15, 2026, and is solely responsible for the information contained therein.